0.05(0.41%) Volume: 2,152,016 4:00PM EDT| Market Cap : 2.01 B | Enterprise Value : 3.35 B | P/E (TTM) : | P/B : 1.96 |
|---|
HZNP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
HZNP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
GuruFocus Financial Strength Rank measures how strong a companys financial situation is. It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| vs
industry |
vs
history |
||
|---|---|---|---|
| Cash-to-Debt | 0.29 |
HZNP's Cash-to-Debt is ranked lower than
76% of the 799 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 2.05 vs. HZNP: 0.29 ) Ranked among companies with meaningful Cash-to-Debt only. |
HZNP'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.07 Med: 0.72 Max: 2.56 Current: 0.29 |
| Equity-to-Asset | 0.25 |
HZNP's Equity-to-Asset is ranked lower than
90% of the 731 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 0.64 vs. HZNP: 0.25 ) Ranked among companies with meaningful Equity-to-Asset only. |
HZNP'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.77 Med: 0.44 Max: 0.7 Current: 0.25 |
| Debt-to-Equity | 1.84 |
HZNP's Debt-to-Equity is ranked lower than
92% of the 568 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 0.30 vs. HZNP: 1.84 ) Ranked among companies with meaningful Debt-to-Equity only. |
HZNP'
s Debt-to-Equity Range Over the Past 10 Years
Min: -2.51 Med: 0.63 Max: 1.84 Current: 1.84 |
| Piotroski F-Score: 4 |
|
| Altman Z-Score: 0.02 |
|
| Beneish M-Score: -3.04 |
|
| WACC vs ROIC |
1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank
| vs
industry |
vs
history |
||
|---|---|---|---|
| Operating Margin % | -42.98 |
HZNP's Operating Margin % is ranked lower than
80% of the 758 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 7.95 vs. HZNP: -42.98 ) Ranked among companies with meaningful Operating Margin % only. |
HZNP'
s Operating Margin % Range Over the Past 10 Years
Min: -1841.5 Med: -57.9 Max: 7.31 Current: -42.98 |
| Net Margin % | -42.40 |
HZNP's Net Margin % is ranked lower than
80% of the 759 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 6.06 vs. HZNP: -42.40 ) Ranked among companies with meaningful Net Margin % only. |
HZNP'
s Net Margin % Range Over the Past 10 Years
Min: -1635.12 Med: -201.31 Max: 5.22 Current: -42.4 |
| ROE % | -35.21 |
HZNP's ROE % is ranked lower than
79% of the 780 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 6.91 vs. HZNP: -35.21 ) Ranked among companies with meaningful ROE % only. |
HZNP'
s ROE % Range Over the Past 10 Years
Min: -523.78 Med: -107.35 Max: 4.27 Current: -35.21 |
| ROA % | -11.24 |
HZNP's ROA % is ranked lower than
75% of the 805 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 3.71 vs. HZNP: -11.24 ) Ranked among companies with meaningful ROA % only. |
HZNP'
s ROA % Range Over the Past 10 Years
Min: -186.55 Med: -59.51 Max: 1.89 Current: -11.24 |
| ROC (Joel Greenblatt) % | -1014.92 |
HZNP's ROC (Joel Greenblatt) % is ranked lower than
89% of the 793 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 13.48 vs. HZNP: -1014.92 ) Ranked among companies with meaningful ROC (Joel Greenblatt) % only. |
HZNP'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -7948.82 Med: -2263.21 Max: 520.88 Current: -1014.92 |
| 3-Year Revenue Growth Rate | 73.80 |
HZNP's 3-Year Revenue Growth Rate is ranked higher than
97% of the 634 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 5.10 vs. HZNP: 73.80 ) Ranked among companies with meaningful 3-Year Revenue Growth Rate only. |
HZNP'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0 Med: 26 Max: 115.5 Current: 73.8 |
| 3-Year EPS without NRI Growth Rate | -23.70 |
HZNP's 3-Year EPS without NRI Growth Rate is ranked lower than
85% of the 576 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 7.60 vs. HZNP: -23.70 ) Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only. |
HZNP'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0 Med: -52 Max: -23.7 Current: -23.7 |
| Ken Heebner 1,000,000 sh (New) Paul Tudor Jones 49,605 sh (New) Steven Cohen 509,400 sh (+41.58%) | Julian Robertson 673,933 sh (-24.66%) |
| Joel Greenblatt 126,466 sh (New) Paul Tudor Jones 104,075 sh (+109.81%) Ken Heebner 1,530,000 sh (+53.00%) Julian Robertson 793,933 sh (+17.81%) Steven Cohen 572,900 sh (+12.47%) |
| Julian Robertson Sold Out Ken Heebner Sold Out Steven Cohen 427,200 sh (-25.43%) Joel Greenblatt 37,797 sh (-70.11%) Paul Tudor Jones 20,100 sh (-80.69%) |
| John Paulson 4,935,500 sh (New) Jim Simons 107,900 sh (New) Steven Cohen 3,653,500 sh (+755.22%) | Paul Tudor Jones Sold Out Joel Greenblatt Sold Out |
(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
| Guru | Date | Trades | Impact to Portfolio | Price Range * (?) | Current Price | Change from Average | Current Shares | |
|---|---|---|---|---|---|---|---|---|
| John Paulson | 2017-06-30 | New Buy | 0.8% | $9.65 - $15.75 | $ 12.32 | -1% | 4,935,500 |  |
| Joel Greenblatt | 2017-06-30 | Sold Out | 0.01% | $9.65 - $15.75 | $ 12.32 | -1% | 0 | |
| Joel Greenblatt | 2017-03-31 | Reduce -70.11% | 0.02% | $14.37 - $18.09 | $ 12.32 | -24% | 37,797 | |
| Julian Robertson | 2017-03-31 | Sold Out | 2.33% | $14.37 - $18.09 | $ 12.32 | -24% | 0 | |
| Ken Heebner | 2017-03-31 | Sold Out | 1.1% | $14.37 - $18.09 | $ 12.32 | -24% | 0 | |
| Ken Heebner | 2016-12-31 | Add 53.00% | 0.38% | $14.55 - $21.7 | $ 12.32 | -32% | 1,530,000 | |
| Julian Robertson | 2016-12-31 | Add 17.81% | 0.35% | $14.55 - $21.7 | $ 12.32 | -32% | 793,933 | |
| Joel Greenblatt | 2016-12-31 | New Buy | 0.03% | $14.55 - $21.7 | $ 12.32 | -32% | 126,466 | |
| Ken Heebner | 2016-09-30 | New Buy | 0.86% | $16.72 - $23.19 | $ 12.32 | -37% | 1,000,000 | |
| Julian Robertson | 2016-09-30 | Reduce -24.66% | 1.17% | $16.72 - $23.19 | $ 12.32 | -37% | 673,933 | |
More recent guru trades are included for Premium Members only!! More recent guru trades are included for USA Subscribe Members only!!
What is Peter Lynch Charts )| Industry: | Drug Manufacturers » Drug Manufacturers - Specialty & Generic NAICS: 325412 SIC: 2834 | |
|---|---|---|
| Compare: | NAS:ENDP, NAS:INNL, NYSE:PRGO, NYSE:AGN » details | |
| Traded in other countries: | HPR.Germany, | |
| Headquarter Location: | Ireland |
| vs
industry |
vs
history |
||
|---|---|---|---|
| Forward PE Ratio | 11.10 |
HZNP's Forward PE Ratio is ranked higher than
81% of the 67 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 18.90 vs. HZNP: 11.10 ) Ranked among companies with meaningful Forward PE Ratio only. |
N/A |
| PB Ratio | 1.96 |
HZNP's PB Ratio is ranked higher than
75% of the 751 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 2.80 vs. HZNP: 1.96 ) Ranked among companies with meaningful PB Ratio only. |
HZNP'
s PB Ratio Range Over the Past 10 Years
Min: 0.8 Med: 2.16 Max: 14.94 Current: 1.96 |
| PS Ratio | 1.94 |
HZNP's PS Ratio is ranked higher than
63% of the 736 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 2.97 vs. HZNP: 1.94 ) Ranked among companies with meaningful PS Ratio only. |
HZNP'
s PS Ratio Range Over the Past 10 Years
Min: 1.47 Med: 4.12 Max: 19 Current: 1.94 |
| Price-to-Free-Cash-Flow | 5.97 |
HZNP's Price-to-Free-Cash-Flow is ranked higher than
93% of the 208 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 25.89 vs. HZNP: 5.97 ) Ranked among companies with meaningful Price-to-Free-Cash-Flow only. |
HZNP'
s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.02 Med: 9.42 Max: 433 Current: 5.97 |
| Price-to-Operating-Cash-Flow | 5.87 |
HZNP's Price-to-Operating-Cash-Flow is ranked higher than
90% of the 277 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 19.02 vs. HZNP: 5.87 ) Ranked among companies with meaningful Price-to-Operating-Cash-Flow only. |
HZNP'
s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.9 Med: 8.94 Max: 209.52 Current: 5.87 |
| EV-to-EBIT | -7.57 |
HZNP's EV-to-EBIT is ranked lower than
99.99% of the 559 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 20.11 vs. HZNP: -7.57 ) Ranked among companies with meaningful EV-to-EBIT only. |
HZNP'
s EV-to-EBIT Range Over the Past 10 Years
Min: -775.4 Med: -1.9 Max: 219.8 Current: -7.57 |
| EV-to-EBITDA | -18.65 |
HZNP's EV-to-EBITDA is ranked lower than
97% of the 587 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 17.50 vs. HZNP: -18.65 ) Ranked among companies with meaningful EV-to-EBITDA only. |
HZNP'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -608 Med: -0.5 Max: 518 Current: -18.65 |
| EV-to-Revenue | 3.26 |
HZNP's EV-to-Revenue is ranked higher than
50% of the 755 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 3.22 vs. HZNP: 3.26 ) Ranked among companies with meaningful EV-to-Revenue only. |
HZNP'
s EV-to-Revenue Range Over the Past 10 Years
Min: 0.5 Med: 5.2 Max: 30.2 Current: 3.26 |
| Current Ratio | 1.61 |
HZNP's Current Ratio is ranked lower than
67% of the 782 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 2.40 vs. HZNP: 1.61 ) Ranked among companies with meaningful Current Ratio only. |
HZNP'
s Current Ratio Range Over the Past 10 Years
Min: 0.16 Med: 1.94 Max: 4.39 Current: 1.61 |
| Quick Ratio | 1.46 |
HZNP's Quick Ratio is ranked lower than
60% of the 782 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 1.82 vs. HZNP: 1.46 ) Ranked among companies with meaningful Quick Ratio only. |
HZNP'
s Quick Ratio Range Over the Past 10 Years
Min: 0.16 Med: 1.65 Max: 4.27 Current: 1.46 |
| Days Inventory | 108.47 |
HZNP's Days Inventory is ranked lower than
57% of the 707 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 117.36 vs. HZNP: 108.47 ) Ranked among companies with meaningful Days Inventory only. |
HZNP'
s Days Inventory Range Over the Past 10 Years
Min: 13.1 Med: 59.25 Max: 184.95 Current: 108.47 |
| Days Sales Outstanding | 138.58 |
HZNP's Days Sales Outstanding is ranked lower than
85% of the 651 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 74.70 vs. HZNP: 138.58 ) Ranked among companies with meaningful Days Sales Outstanding only. |
HZNP'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 67.08 Med: 90.85 Max: 138.58 Current: 138.58 |
| Days Payable | 59.28 |
HZNP's Days Payable is ranked lower than
51% of the 600 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 70.96 vs. HZNP: 59.28 ) Ranked among companies with meaningful Days Payable only. |
HZNP'
s Days Payable Range Over the Past 10 Years
Min: 27.59 Med: 183.99 Max: 410.36 Current: 59.28 |
| vs
industry |
vs
history |
||
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -34.70 |
HZNP's 3-Year Average Share Buyback Ratio is ranked lower than
92% of the 473 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: -4.10 vs. HZNP: -34.70 ) Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only. |
HZNP'
s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -428.1 Med: -61.1 Max: 0 Current: -34.7 |
| vs
industry |
vs
history |
||
|---|---|---|---|
| Price-to-Intrinsic-Value-Projected-FCF | 1.02 | ||
| Price-to-Median-PS-Value | 0.47 |
HZNP's Price-to-Median-PS-Value is ranked higher than
93% of the 712 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 1.09 vs. HZNP: 0.47 ) Ranked among companies with meaningful Price-to-Median-PS-Value only. |
HZNP'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.42 Med: 1.02 Max: 4.12 Current: 0.47 |
| Earnings Yield (Greenblatt) % | -13.21 |
HZNP's Earnings Yield (Greenblatt) % is ranked lower than
82% of the 805 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 3.10 vs. HZNP: -13.21 ) Ranked among companies with meaningful Earnings Yield (Greenblatt) % only. |
HZNP'
s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1744.4 Med: -5.55 Max: 2.6 Current: -13.21 |
| Revenue (TTM) (Mil) $ | 1,029.42 |
|---|---|
| EPS (TTM) $ | -2.70 |
| Beta | 0.57 |
| Short Percentage of Float | 12.37% |
| 52-Week Range $ | 9.45 - 21.98 |
| Shares Outstanding (Mil) | 163.35 |
| Dec17 | Dec18 | Dec19 | |
|---|---|---|---|
| Revenue (Mil $) | 1,047 | 1,101 | 1,177 |
| EPS ($) | 1.00 | 1.11 | 1.60 |
| EPS without NRI ($) | 1.00 | 1.11 | 1.60 |
| EPS Growth Rate (Future 3Y To 5Y Estimate) | N/A | ||
| Dividends per Share ($) | |||
GF Chat
Excel Add-In GURUF
API
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
My Gurus
Email Alerts
Stock PDF
RSS
Website
Filings
Manual of Stocks™ Web APP